Highly sensitive detection of driver mutations from cytological samples and cfDNA in lung cancer

Código QR

Highly sensitive detection of driver mutations from cytological samples and cfDNA in lung cancer

Abstract Background Bronchoscopy is a minimally invasive procedure for establishing the diagnosis of lung cancer. It sometimes fails to obtain tissue samples but readily collects cytological samples. Methods We developed PNA‐LNA dual‐PCR (PLDP), which amplified mutant sequences by a high‐fidelity DN...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kazutaka Fujita, Masayuki Nakayama, Masafumi Sata, Yoshiaki Nagai, Shu Hisata, Naoko Mato, Takuji Suzuki, Masashi Bando, Nobuyuki Hizawa, Koichi Hagiwara
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	cell‐free DNA cytological samples EGFR mutation lung cancer secondary mutation Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/d401f2ddbd7f445f8908f840d1ed0e76
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis
por: Kate S, et al.
Publicado: (2019)

Uncommon EGFR mutations in cytological specimens of 1,874 newly diagnosed Indonesian lung cancer patients
por: Syahruddin E, et al.
Publicado: (2018)

Value and significance of brain radiation therapy during first‐line EGFR‐TKI treatment in lung adenocarcinoma with EGFR sensitive mutation and synchronous brain metastasis: Appropriate timing and technique
por: Yangchun Gu, et al.
Publicado: (2021)

Comparing survival and treatment response of patients with acquired T790M mutation second‐line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A real‐world study
por: Chin‐Chou Wang, et al.
Publicado: (2021)

Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature
por: Michela Verzè, et al.
Publicado: (2021)

Identification of the Unique Clinical and Genetic Features of Chinese Lung Cancer Patients With EGFR Germline Mutations in a Large-Scale Retrospective Study
por: Xinqing Lin, et al.
Publicado: (2021)

Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin
por: Elli Narvi, et al.
Publicado: (2018)

Favorable Immune Microenvironment in Patients with EGFR and MAPK Co-Mutations
por: Yang W, et al.
Publicado: (2020)

BRCA1 and BRCA2mutations in breast cancer patients from Venezuela
por: Lara,Karlena, et al.
Publicado: (2012)

Case Report: Dacomitinib Overcomes Osimertinib Resistance in NSCLC Patient Harboring L718Q Mutation: A Case Report
por: Qian Shen, et al.
Publicado: (2021)

Experience of Uncommon EGFR Mutation in Lung Scheme Quality Program: Discussing Risks and Opportunities for the Improvement of Laboratory Response
por: Alessandro Pancrazzi, et al.
Publicado: (2021)

<i>APC</i> and <i>TP53</i> Mutations Predict Cetuximab Sensitivity across Consensus Molecular Subtypes
por: Ramya Thota, et al.
Publicado: (2021)

Oral Squamous Cell Carcinoma in Young Patients Show Higher Rates of EGFR Amplification: Implications for Novel Personalized Therapy
por: Laveniya Satgunaseelan, et al.
Publicado: (2021)

Precise Identification of Recurrent Somatic Mutations in Oral Cancer Through Whole-Exome Sequencing Using Multiple Mutation Calling Pipelines
por: Li-Han Lin, et al.
Publicado: (2021)

Clinicopathological characteristics of breast cancer patients with NOD2 mutation according to age
por: Joanna Huszno, et al.
Publicado: (2020)

Case Report: Sequential Combination Targeted Therapy With Type I and II MET Inhibitors in a Metastatic EGFR-Mutated, MET-Amplified NSCLC Patient With Acquired MET Y1230H Mutation
por: Boning Cai, et al.
Publicado: (2021)

Molecular genetic portrait of non-small cell lung cancer in Tambov region: regional experience
por: N. A. Ognerubov, et al.
Publicado: (2020)

A Nexus model of cellular transition in cancer
por: Yadav,Mukesh, et al.
Publicado: (2018)

Analysis of Mutations and Dysregulated Pathways Unravels Carcinogenic Effect and Clinical Actionability of Mutational Processes
por: Zedong Jiang, et al.
Publicado: (2021)

High quality of 58-month life in lung cancer patient with brain metastases sequentially treated with gefitinib and osimertinib
por: Zhang Ying, et al.
Publicado: (2021)

Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
por: Santarpia M, et al.
Publicado: (2017)

Polymer nanofiber-based microchips for EGFR mutation analysis of circulating tumor cells in lung adenocarcinoma
por: Jiang WT, et al.
Publicado: (2018)

Profile of Basal Cell Carcinoma Mutations and Copy Number Alterations - Focus on Gene-Associated Noncoding Variants
por: Paulina Maria Nawrocka, et al.
Publicado: (2021)

Gallbladder Cancer: Current Insights in Genetic Alterations and Their Possible Therapeutic Implications
por: Hendrien Kuipers, et al.
Publicado: (2021)

Frecuencia de la mutación 185delAG en el gen BRCA1 en mujeres chilenas sanas con antecedentes familiares de cáncer de mama
por: Jara S,Lilian, et al.
Publicado: (2002)

Driver oncogenes in Sub-Saharan African patients with non-small cell lung cancer
por: Legius B, et al.
Publicado: (2016)

CRISPR and KRAS: a match yet to be made
por: Guzide Bender, et al.
Publicado: (2021)

Analysis of 5382insC (BRCA1) and 6174delT (BRCA2) mutations in 382 healthy Chilean women with a family history of breast cancer
por: JARA,LILIAN, et al.
Publicado: (2002)

Analysis of KRAS Mutation Subtype in Tissue DNA and Cell-Free DNA Using Droplet Digital PCR and the Function of Cell-Free DNA as a Recurrence Predictive Marker in Pancreatic Cancer
por: Eunsung Jun, et al.
Publicado: (2021)

A Global Mutational Profile of SARS-CoV-2: A Systematic Review and Meta-Analysis of 368,316 COVID-19 Patients
por: Wardah Yusof, et al.
Publicado: (2021)

Role and place of PARP inhibitors in the modern treatment algorithm of BRCA-associated HER2-negative metastatic breast cancer. Results of the educational and discussion events based on the “OncoForum” platform
por: Editorial Board
Publicado: (2021)

Prediction of BRCA gene mutation status in epithelial ovarian cancer by radiomics models based on 2D and 3D CT images
por: Liu Mingzhu, et al.
Publicado: (2021)

KRAS and NRAS genes mutations as biomarkers in the therapy of colorectal cancer and the basic methods of their detection
por: Olga I. Brovkina, et al.
Publicado: (2021)

A Triptolide Loaded HER2-Targeted Nano-Drug Delivery System Significantly Suppressed the Proliferation of HER2-Positive and BRAF Mutant Colon Cancer
por: Yalikong A, et al.
Publicado: (2021)

Cancer Evo–Dev: A Theory of Inflammation-Induced Oncogenesis
por: Wenbin Liu, et al.
Publicado: (2021)

Afatinib for the treatment of advanced non-small-cell lung cancer harboring an epidermal growth factor receptor exon 18 E709_T710delinsD mutation: a case report
por: Lander Van Acker, et al.
Publicado: (2021)

Case Report: Malignant Primary Sellar Paraganglioma With Unusual Genetic and Imaging Features
por: Stefan Stojanoski, et al.
Publicado: (2021)

Host-specific asymmetric accumulation of mutation types reveals that the origin of SARS-CoV-2 is consistent with a natural process
por: Ke-Jia Shan, et al.
Publicado: (2021)

Orthogonal MET analysis in a population‐representative stage II–III colon cancer cohort: prognostic and potential therapeutic implications
por: Stephanie G. Craig, et al.
Publicado: (2021)

Clinical, Pathological, and Molecular Features of Breast Carcinoma Cutaneous Metastasis
por: Silvia González-Martínez, et al.
Publicado: (2021)